More on SCYX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-258.8% Growth)
- Ratings (10.0 Score)
- Holders

Upcoming Events

- Earnings (11/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Scynexis (NQ:SCYX)
Delayed: 3.67 -0.24 (6.14%)
Prev. Close $3.91  
Open$3.87 
52 Wk High$7.29 
52 Wk Low$1.74 
Day High$3.88 
Day Low$3.54 
P/E N/A  
EPS$0.00 
Volume188,985 

Friends, Peers and Foes (?): POXEL, CRVO FR00124325 (more...)

Oct 6, 2026 07:30 AM Scynexis reports Phase 1 results for SCY-770 kidney disease drug
Oct 6, 2026 07:30 AM SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sep 28, 2026 04:01 PM Form 8-K SCYNEXIS INC For: Sep 25
Sep 28, 2026 09:42 AM Scynexis stock surges on $214M BARDA contract for SCY-247
Sep 28, 2026 07:30 AM Scynexis wins BARDA contract worth up to $214M for SCY-247
Sep 28, 2026 07:30 AM SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
Sep 22, 2026 04:02 PM Form 4 SCYNEXIS INC For: Sep 18 Filed by: Burke Steven Keith
Sep 22, 2026 04:01 PM Form 3 SCYNEXIS INC For: Sep 18 Filed by: Burke Steven Keith
Sep 22, 2026 08:05 AM Form 8-K SCYNEXIS INC For: Sep 18
Sep 22, 2026 08:01 AM Scynexis names kidney disease drug developer Steven Burke to board
View All Articles

Entities mentioned with SCYX

View All Entities